Table 1.

Data Relating to Each Contributing Data Set and Combined Cohort, Including Patient Number, Follow-Up, and Disease-Specific Survival

Institution	Total contribution	Inclusion dates	Median follow-up of censored patients (years)	Range follow-up of censored patients (years)	DSS—5 years	DSS—10 years
Combined	9484	1963–2012	5.3	0–44.0	98.3%	96.9%
Memorial Sloan Kettering Cancer Center	2173	2005–2010	3.3	0–9.5	99.10%	Not reached
University of Manitoba	1998	1970–2010	11.4	0–43.9	97.20%	95.70%
University of California, San Francisco	1851	1994–2004	4.6	0–25.4	98.20%	97.40%
University of Sydney Endocrine Surgical Unit	1129	1963–2012	3.0	0–44.0	98.20%	96.20%
Mount Sinai Hospital, Toronto	925	1963–2011	6.0	0–43.9	99.10%	97.50%
Endocrine Service, Instituto Nacional do Cancer/Universidade Federal do Rio de Janeiro	646	1986–2014	8.3	2.7–28	99.40%	97.30%
Barretos Cancer Hospital/ACCamargo Cancer Center	519	1980–2001	7.5	0–25.1	96.90%	96.10%
MD Anderson	243	2005–2012	3.8	0.5–8.3	100%	Not reached

DSS, disease-specific survival.